Literature DB >> 10717344

Preparation and characterisation of quillaja saponin with less heterogeneity than Quil-A.

S Kamstrup1, R San Martin, A Doberti, H Grande, K Dalsgaard.   

Abstract

Immunisation against pathogens remains one of the most effective ways of preventing or reducing losses due to infectious diseases in animal husbandry. When inactivated vaccines are used, adjuvants are most often required to obtain satisfactory immune responses. One such type of adjuvant is saponin derived from the bark of Quillaja saponaria Molina, a tree of the rose family. A few different commercial sources exist, but due to the structural complexity and heterogeneity of these saponin preparations, it has been difficult to establish exactly which components are responsible for the adjuvant activity. By carefully selecting the bark source, we have succeeded in preparing a much less heterogeneous preparation of quillaja saponin. In this report we describe the preparation, in terms of structural complexity, hemolytic activity, adjuvant activity, and its ability to form ISCOM matrix. This new preparation could have implications for use per se, or as starting material for more effective preparation of pure substances.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10717344     DOI: 10.1016/s0264-410x(99)00560-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

Authors:  Kai Deng; Michelle M Adams; Payal Damani; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

2.  Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A.

Authors:  Karen White; Thomas Rades; Philip Kearns; Istvan Toth; Sarah Hook
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

Review 3.  Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.

Authors:  Govind Ragupathi; Jeffrey R Gardner; Philip O Livingston; David Y Gin
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

4.  Enhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant.

Authors:  David Y Gin; Susan F Slovin
Journal:  Curr Drug ther       Date:  2011-08

5.  The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.

Authors:  Claire Swetman Andersen; Jes Dietrich; Else Marie Agger; Nils Y Lycke; Karin Lövgren; Peter Andersen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

6.  Design and synthesis of potent Quillaja saponin vaccine adjuvants.

Authors:  Michelle M Adams; Payal Damani; Nicholas R Perl; Annie Won; Feng Hong; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  J Am Chem Soc       Date:  2010-02-17       Impact factor: 15.419

7.  Versatile strategy for the divergent synthesis of linear oligosaccharide domain variants of Quillaja saponin vaccine adjuvants.

Authors:  Alberto Fernández-Tejada; Derek S Tan; David Y Gin
Journal:  Chem Commun (Camb)       Date:  2015-09-21       Impact factor: 6.222

8.  Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.

Authors:  Alberto Fernández-Tejada; Eric K Chea; Constantine George; Jeffrey R Gardner; Philip O Livingston; Govind Ragupathi; Derek S Tan; David Y Gin
Journal:  Bioorg Med Chem       Date:  2014-09-17       Impact factor: 3.641

9.  Vaccine Adjuvants Derivatized from Momordica Saponins I and II.

Authors:  Pengfei Wang; Xiong Ding; Hyunjung Kim; Đani Škalamera; Suzanne M Michalek; Ping Zhang
Journal:  J Med Chem       Date:  2019-10-28       Impact factor: 7.446

10.  Structural Effect on Adjuvanticity of Saponins.

Authors:  Pengfei Wang; Xiong Ding; Hyunjung Kim; Suzanne M Michalek; Ping Zhang
Journal:  J Med Chem       Date:  2020-02-26       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.